For instance, valeric acid, a newly reported HDAC2 inhibitor, has shown high efficacy against tumors with low toxicity to normal cells and holds the potential to be a qualified candidate for combination therapy with PD-1 inhibitors in the treatment of HCC. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.